Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus
References (32)
- et al.
Solution structure of ω-conotoxin MVIIA using 2D NMR spectroscopy
FEBS Lett.
(1995) Calcium: still center-stage in hypoxic–ischemic neuronal death
Trends Neurosci.
(1995)- et al.
Solution structure of ω-conotoxin MVIIC, a high affinity ligand of P-type calcium channels, using 1H NMR spectroscopy and complete relaxation matrix analysis
J. Mol. Biol.
(1995) - et al.
Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium channel antagonist, SNX-230 (ω-conopeptide MVIIC)
Brain Res.
(1994) - et al.
Characterization of the binding of omega-conopeptides to different classes of non-L-type neuronal calcium channels
Mol. Cell Neurosci.
(1994) - et al.
Effect of continuous intrathecal infusion of ω-conopeptides, N-type calcium channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats
Pain
(1995) - et al.
Identifying neuronal non-L Ca2+ channels: more than stamp collecting?
TiPS
(1997) - et al.
Conotoxins
J. Biol. Chem.
(1991) - et al.
Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain
J. Pharmacol. Exp. Ther.
(1996) - et al.
Selective blockade of N-type voltage-sensitive calcium channels protects against brain injury after transient focal cerebral ischemia in rats
Brain Res.
(1997)
Use of intrathecal SNX-111, a novel N-type, voltage-sensitive calcium channel blocker, in the management of intractable brachial avulsion pain
Clin. J. Pain
A selective N-type Ca2+ blocker prevents CA1 injury 24 h after severe forebrain ischemia and reduces infarction following focal ischemia
J. Cereb. Blood Flow Metab.
Determination of disulfide bridge pattern in ω-conopeptides
Int. J. Peptide Protein Res.
Solution structure of ω-conotoxin GVIA using 2D NMR spectroscopy and relaxation matrix analysis
Biochemistry
Molecular basis for Ca2+ diversity
Annu. Rev. Neurosci.
Cited by (106)
Central IRAK-4 kinase inhibition for the treatment of pain following nerve injury in rats
2020, Brain, Behavior, and ImmunityThe application of sulfur-containing peptides in drug discovery
2018, Chinese Chemical LettersCitation Excerpt :Ziconotide (Prialt, Fig. 3), developed by Elan and approved by FDA and EMA in 2005, is a synthetic ω-conotoxin polypeptide. As a blocking agent for N-type calcium channel (NCC), it is much safe and effective for neurotherapeutics [38,39]. Ziconotide consists of 25 amino acids and three disulfide bonds which determine its’ pharmacological activity.
Cisplatin-induced neuropathic pain is mediated by upregulation of N-type voltage-gated calcium channels in dorsal root ganglion neurons
2017, Experimental NeurologyCitation Excerpt :In accordance to the literature 1.5 mg/kg cisplatin was sufficient to induce typical signs of cisplatin-induced polyneuropathy as heat hyperalgesia and mechanical allodynia in rat (Joseph and Levine, 2009). Intrathecal treatment with Ɯ-conotoxin MVIIA alleviated pain-associated behaviors (Bowersox and Luther, 1998; Malmberg and Yaksh, 1995; Snutch, 2005; Vanegas and Schaible, 2000; Wallace, 2006). A relationship between neuropathic pain induced by oxaliplatin and the inhibition of L-type VGCCs was recently demonstrated (Kawashiri et al., 2012).
Voltage-Gated Calcium Channel Blockers for the Treatment of Traumatic Brain Injury
2017, New Therapeutics for Traumatic Brain Injury: Prevention of Secondary Brain Damage and Enhancement of Repair and Regeneration